Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15,210 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts.
Ono T, Takeshita A, Kishimoto Y, Kiyoi H, Okada M, Yamauchi T, Emi N, Horikawa K, Matsuda M, Shinagawa K, Monma F, Ohtake S, Nakaseko C, Takahashi M, Kimura Y, Iwanaga M, Asou N, Naoe T; Japan Adult Leukemia Study Group. Ono T, et al. Among authors: takahashi m. Cancer Sci. 2014 Jan;105(1):97-104. doi: 10.1111/cas.12319. Epub 2014 Jan 9. Cancer Sci. 2014. PMID: 24206578 Free PMC article. Clinical Trial.
A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T, Takahashi M, Ogawa Y, Honda S, Ohno R; Japan Adult Leukemia Study Group AML 97 Study. Miyawaki S, et al. Among authors: takahashi m. Cancer. 2005 Dec 15;104(12):2726-34. doi: 10.1002/cncr.21493. Cancer. 2005. PMID: 16284985 Free article. Clinical Trial.
Long-term outcome and prognostic factors of elderly patients with acute promyelocytic leukemia.
Ono T, Takeshita A, Kishimoto Y, Kiyoi H, Okada M, Yamauchi T, Tsuzuki M, Horikawa K, Matsuda M, Shinagawa K, Monma F, Ohtake S, Nakaseko C, Takahashi M, Kimura Y, Iwanaga M, Asou N, Naoe T; Japan Adult Leukemia Study Group. Ono T, et al. Among authors: takahashi m. Cancer Sci. 2012 Nov;103(11):1974-8. doi: 10.1111/j.1349-7006.2012.02390.x. Epub 2012 Sep 18. Cancer Sci. 2012. PMID: 22834728 Free PMC article.
The demarcation between younger and older acute myeloid leukemia patients: a pooled analysis of 3 prospective studies.
Yanada M, Ohtake S, Miyawaki S, Sakamaki H, Sakura T, Maeda T, Miyamura K, Asou N, Oh I, Miyatake J, Kanbayashi H, Takeuchi J, Takahashi M, Dobashi N, Kiyoi H, Miyazaki Y, Emi N, Kobayashi Y, Ohno R, Naoe T; Japan Adult Leukemia Study Group. Yanada M, et al. Among authors: takahashi m. Cancer. 2013 Sep 15;119(18):3326-33. doi: 10.1002/cncr.28212. Epub 2013 Jun 24. Cancer. 2013. PMID: 23798329 Free article. Clinical Trial.
A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study.
Asou N, Kishimoto Y, Kiyoi H, Okada M, Kawai Y, Tsuzuki M, Horikawa K, Matsuda M, Shinagawa K, Kobayashi T, Ohtake S, Nishimura M, Takahashi M, Yagasaki F, Takeshita A, Kimura Y, Iwanaga M, Naoe T, Ohno R; Japan Adult Leukemia Study Group. Asou N, et al. Among authors: takahashi m. Blood. 2007 Jul 1;110(1):59-66. doi: 10.1182/blood-2006-08-043992. Epub 2007 Mar 20. Blood. 2007. PMID: 17374742 Free article. Clinical Trial.
Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study.
Ohtake S, Miyawaki S, Kiyoi H, Miyazaki Y, Okumura H, Matsuda S, Nagai T, Kishimoto Y, Okada M, Takahashi M, Handa H, Takeuchi J, Kageyama S, Asou N, Yagasaki F, Maeda Y, Ohnishi K, Naoe T, Ohno R. Ohtake S, et al. Among authors: takahashi m. Int J Hematol. 2010 Mar;91(2):276-83. doi: 10.1007/s12185-009-0480-5. Int J Hematol. 2010. PMID: 20054669 Clinical Trial.
Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study.
Sakamaki H, Miyawaki S, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Takahashi M, Ogawa Y, Honda S, Ohno R. Sakamaki H, et al. Among authors: takahashi m. Int J Hematol. 2010 Mar;91(2):284-92. doi: 10.1007/s12185-009-0483-2. Int J Hematol. 2010. PMID: 20063133 Clinical Trial.
Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study.
Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, Okumura H, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R. Ohtake S, et al. Among authors: takahashi m. Blood. 2011 Feb 24;117(8):2358-65. doi: 10.1182/blood-2010-03-273243. Epub 2010 Aug 6. Blood. 2011. PMID: 20693429 Free article. Clinical Trial.
A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study.
Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N, Sakura T, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R. Miyawaki S, et al. Among authors: takahashi m. Blood. 2011 Feb 24;117(8):2366-72. doi: 10.1182/blood-2010-07-295279. Epub 2010 Dec 29. Blood. 2011. PMID: 21190996 Free article. Clinical Trial.
CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21).
Iriyama N, Hatta Y, Takeuchi J, Ogawa Y, Ohtake S, Sakura T, Mitani K, Ishida F, Takahashi M, Maeda T, Izumi T, Sakamaki H, Miyawaki S, Honda S, Miyazaki Y, Taki T, Taniwaki M, Naoe T. Iriyama N, et al. Among authors: takahashi m. Leuk Res. 2013 Sep;37(9):1021-6. doi: 10.1016/j.leukres.2013.05.002. Epub 2013 Jun 28. Leuk Res. 2013. PMID: 23810283 Clinical Trial.
15,210 results
You have reached the last available page of results. Please see the User Guide for more information.